2018
Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin
Vashisht R, Jung K, Schuler A, Banda J, Park R, Jin S, Li L, Dudley J, Johnson K, Shervey M, Xu H, Wu Y, Natrajan K, Hripcsak G, Jin P, Van Zandt M, Reckard A, Reich C, Weaver J, Schuemie M, Ryan P, Callahan A, Shah N. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin. JAMA Network Open 2018, 1: e181755. PMID: 30646124, PMCID: PMC6324274, DOI: 10.1001/jamanetworkopen.2018.1755.Peer-Reviewed Original ResearchConceptsDPP-4 inhibitorsDipeptidyl peptidase-4 inhibitorsFirst-line therapyPeptidase-4 inhibitorsSecond-line drugsType 2 diabetesMyocardial infarctionEye disordersKidney disordersDrug classesSecond-line treatment choiceTotal hemoglobinObservational Health Data SciencesSecond-line treatment optionNew-user cohort studyEffectiveness of sulfonylureasSecond-line treatmentHemoglobin A1c levelsUse of sulfonylureasHealth Data SciencesLarge international studyElectronic medical recordsRoutine medical practiceInsurance claims dataCohort study
2017
Risk of angioedema associated with levetiracetam compared with phenytoin: Findings of the observational health data sciences and informatics research network
Duke J, Ryan P, Suchard M, Hripcsak G, Jin P, Reich C, Schwalm M, Khoma Y, Wu Y, Xu H, Shah N, Banda J, Schuemie M. Risk of angioedema associated with levetiracetam compared with phenytoin: Findings of the observational health data sciences and informatics research network. Epilepsia 2017, 58: e101-e106. PMID: 28681416, PMCID: PMC6632067, DOI: 10.1111/epi.13828.Peer-Reviewed Original ResearchConceptsAngioedema riskAngioedema eventsHazard ratioObservational Health Data SciencesNew-user cohort studySummary hazard ratioRisk of angioedemaHealth Data SciencesAdverse event reportsPhenytoin usersResearch NetworkPhenytoin groupCohort studyTreat analysisAntiepileptic drugsComparator groupSeizure patientsLower riskLevetiracetamAngioedemaFurther studiesEvent reportsSignificant increaseRiskPhenytoin